SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX
Clinical trials for SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX explained in plain language.
Never miss a new study
Get alerted when new SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX trials appear
Sign up with your email to follow new studies for SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare cancer: targeted drug afatinib tested in fanconi anemia patients
Disease control Recruiting nowThis study tests a drug called afatinib in 25 adults with Fanconi anemia who have advanced head and neck cancer that cannot be removed by surgery. Afatinib is a pill that blocks a protein helping cancer grow. The goal is to see if it can shrink tumors and control the disease. Res…
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX
Phase: PHASE1, PHASE2 • Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Could a 3-Week radiation course replace 6 weeks for head and neck cancer?
Disease control Recruiting nowThis study compares a standard 6-week radiation course after surgery to a shorter 3-week course for people with head and neck cancer. The goal is to see if the shorter schedule works just as well at preventing cancer from coming back. About 369 participants will be randomly assig…
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX
Phase: PHASE2, PHASE3 • Sponsor: All India Institute of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Could less radiation be better for head and neck cancer?
Disease control Recruiting nowThis study is for people with head and neck cancer. It compares two types of radiation therapy: one that treats only the cancer and nearby lymph nodes (INRT) and one that treats a larger area (ENI). The goal is to see if the smaller treatment area works just as well and causes fe…
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX
Phase: PHASE2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Could less radiation be better for head and neck cancer patients?
Disease control Recruiting nowThis study tests whether giving less radiation after surgery for certain head and neck cancers can reduce long-term side effects, like trouble swallowing, without allowing the cancer to come back. About 508 adults who have had surgery and need standard post-op radiation will be r…
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX
Phase: PHASE2, PHASE3 • Sponsor: University of Erlangen-Nürnberg Medical School • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Stick it out: simple tongue trick could ease radiation side effects
Symptom relief Recruiting nowThis study tests a simple technique called tongue-out radiation therapy (TORT) for people with head and neck cancer. By sticking out the tongue during treatment, the radiation dose to the mouth and throat may be lowered, potentially reducing painful side effects like trouble swal…
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX
Phase: NA • Sponsor: Yvonne Mowery • Aim: Symptom relief
Last updated Jun 27, 2026 08:03 UTC
-
Lab-Grown tumor clones could guide cancer therapy
Knowledge-focused Recruiting nowThis study aims to grow miniature versions of head and neck tumors, called organoids, from patient samples. Researchers will test different cancer drugs on these organoids to see which ones work best. The goal is to eventually use this approach to tailor treatments to each patien…
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX
Sponsor: Centre Francois Baclesse • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Can immune markers predict success of docetaxel chemoradiotherapy?
Knowledge-focused Recruiting nowThis study looks at immune markers in tumor tissue, saliva, stool, and blood from 250 head and neck cancer patients who cannot receive cisplatin chemotherapy. Researchers want to see if these markers can predict how well patients respond to chemoradiotherapy with docetaxel. The g…
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX
Sponsor: University of Erlangen-Nürnberg Medical School • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC